Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation

Abstract Background Empagliflozin (EMPA) has demonstrated efficacy in providing cardiovascular benefits in metabolic diseases. However, the direct effect of EMPA on autophagy in obesity-related cardiac dysfunction remains unclear. Therefore, this study aimed to determine changes in cardiac autophagy...

Full description

Bibliographic Details

Published in:	Lipids in Health and Disease
Main Authors:	Youhong Luo, Tongtong Ye, Hongzhan Tian, Hongwei Song, Chengxia Kan, Fang Han, Ningning Hou, Xiaodong Sun, Jingwen Zhang
Format:	Article
Language:	English
Published:	BMC 2024-09-01
Subjects:	Obesity-related cardiac dysfunction Empagliflozin SIRT3 Autophagy
Online Access:	https://doi.org/10.1186/s12944-024-02293-9